Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Merck reported Q2 2026 sales of $16.6 billion, up 5% year-over-year, driven by strong growth in oncology and animal health. GAAP EPS was a loss of $0.54 due to a $2.31 per share charge for the acquisition of Terns; excluding this, Non-GAAP EPS was a loss of $0.13.
Key figures
- Revenue
- $16.6 billion
- Guidance
- FY2026 sales $66.3B-$67.3B; Non-GAAP EPS $2.66-$2.76
- Revenue Yoy
- 5%
- Deal Value Usd
- 6800000000
- Rd expenses
- $9.7 billion
- Keytruda sales
- $8.4 billion
- Terns charge per share
- 2.31
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.